Bee Vectoring Technologies International (TSE:BEE) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Bee Vectoring Technologies International Inc. has reported a successful trial of their CR-7 biofungicide at Michigan State University, demonstrating a dramatic 90% reduction in fungal diseases in blueberries. The trial, which showed CR-7 to be as effective as traditional chemical treatments, suggests potential for the product’s use in various applications beyond the initial bee vectoring technique. This innovation could transform disease management in blueberry farming and improve crop yield and quality by effectively controlling the prevalent mummy berry pathogen.
For further insights into TSE:BEE stock, check out TipRanks’ Stock Analysis page.
